The efficacy and tolerability of co‐targeting ALK with MEK (NCT03202940, NCT03087448) or mTORC1 (NCT02321501) are currently tested in patients with ALK‐rearranged NSCLC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.